LP
IKT icon

LMR Partners’s Inhibikase Therapeutics IKT Stock Holding History

LMR Partners’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,092
Closed -$60.6K – 1541
2025
Q2 		$60.6K Hold
31,092
– – ﹤0.01% 1206
2025
Q1 		$68.1K Buy
+31,092
New +$78.1K ﹤0.01% 1179

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

LMR Partners's IKT Position: Q3 2025 in Review

LMR Partners sold out of Inhibikase Therapeutics (IKT) in Q3 2025, closing a stake of 31,092 shares — an estimated $60.6K sold.

LMR Partners first reported a position in IKT in Q1 2025 and held it in 2 quarters. The position peaked at $68.1K in Q1 2025. 54 funds tracked by Wall St. Rank hold IKT as of Q3 2025.

  • LMR Partners reported no remaining Inhibikase Therapeutics position as of Q3 2025 after selling out during the quarter.
  • LMR Partners sold 31,092 Inhibikase Therapeutics shares in Q3 2025, an estimated $60.6K.
  • LMR Partners first reported a position in Inhibikase Therapeutics in Q1 2025 and held it in 2 quarters.
  • LMR Partners's Inhibikase Therapeutics position peaked at $68.1K in Q1 2025.
  • 54 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2025.

Based on LMR Partners's 13F filing for Q3 2025, filed 14 Nov 2025.